Research Article | | Peer-Reviewed

Senegalese Experience of Pseudo Hypoparathyroidism About Three Cases at the Department of Neurology in Fann Teaching Hospital

Received: 3 October 2023     Accepted: 1 November 2023     Published: 18 December 2023
Views:       Downloads:
Abstract

Pseudohypoparathyroidism is a group of rare, related and highly heterogeneous disorders characterized by target organ resistance to the action of parathyroid hormone. Pseudohypoparathyroidism and related disorders are caused by genetic and/or epigenetic changes resulting in downregulation of a cyclic adenosine mono phosphate generator primarily linked to the GNAS gene, patients who have experienced hormonal parathyroid (hypocalcemia and hyperphosphatemia resistant to parathyroid hormone with characteristic skeletal and developmental changes. Multiple transcript variants encoding different isoforms have been found for this gene. Mutations in this gene result in pseudohypoparathyroidism type 1a, pseudohypoparathyroidism type 1b, hereditary osteodystrophy; Albright, pseudohypoparathyroidism, McCune-Albright syndrome, progressive bone heteroplasia, polyostotic fibrous dysplasia of bone, and certain pituitary tumors Here we report a series of 3 cases carrying pseudohypopathyroidism, their sociodemographic, clinical and paraclinical aspects as well as therapeutic.

Published in International Journal of Medical Case Reports (Volume 2, Issue 4)
DOI 10.11648/j.ijmcr.20230204.12
Page(s) 28-35
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2023. Published by Science Publishing Group

Keywords

Pseudohypoparathyroidism, PTH Resistance, Subcutaneous Ossifications, Brachydactyly

References
[1] Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993.
[2] Boody BS, Lendner M, Vaccaro AR. Ossification of the posterior longitudinal ligament in the cervical spine: a review. Int Orthop. 2019; 43 (4): 797-805.
[3] Chaabène A, Kamoun F, Charfi N, Triki C, Abid M, Mhiri C. Hypocalcemic epileptic seizures: study of 7 cases. Epilepsies. 2006; 18 (3): 149-154.
[4] Cho D, Min B, Kim J, Lee B. EEG-based prediction of epileptic seizures using phase synchronization elicited from noise-assisted multivariate empirical mode decomposition. IEEE Trans Neural Syst Rehabil Eng. 2016; 25 (8): 1309-1318.
[5] Craigie EH. On the relative vascularity of various parts of the central nervous system of the albino rat. J Comp Neurol. 1920; 31 (5): 429-464.
[6] Davies SJ, Hughes HE. Imprinting in Albright's hereditary osteodystrophy. J Med Genet. 1993; 30 (2): 101-103.
[7] De Silva SW, De Silva SDN, De Silva CE. A patient with extensive cerebral calcification due to pseudohypoparathyroidism: a case report. BMC Endocr Disord. 2019; 19 (1): 142.
[8] Del Monte P, Cuttica CM, Marugo A, Foppiani L, Audenino D, Godowicz TT, et al. Unrecognized Pseudohypoparathyroidism Type 1A as a Cause of Hypocalcemia and Seizures in a 64-Year-Old Woman. Case Rep Endocrinol. 2019; 2019: 8456239.
[9] Doty RL, Fernandez AD, Levine MA, Moses A, McKeown DA. Olfactory Dysfunction in Type I Pseudohypoparathyroidism: Dissociation from Gs α Protein Deficiency*. J Clin Endocrinol Metab. 1997; 82 (1): 247-250.
[10] Farfel Z, FRIEDMAN E. Mental deficiency in pseudohypoparathyroidism type I is associated with Ns-protein deficiency. Ann Intern Med. 1986; 105 (2): 197-199.
[11] Fitch N, Opitz JM, Herrmann J. Albright's hereditary osteodystrophy: a review. Am J Med Genet. 1982; 11 (1): 11-29.
[12] Foldvary-Schaefer N, Unnwongse K. Localizing and lateralizing features of auras and seizures. Epilepsy Behav. 2011; 20 (2): 160-166.
[13] Garavelli L, Pedori S, Zanacca C, Caselli G, Loiodice A, Mantovani G, et al. Albright's hereditary osteodystrophy (pseudohypoparathyroidism type Ia): clinical case with a novel mutation of GNAS1. Acta Biomed. 2005; 76 (1): 45-48.
[14] Gibberd FB. Spinal cord compression associated with pseudohypoparathyroidism. JR Soc Med. 1990; 83 (7): 477.
[15] Ginat DT, Meyers SP. Intracranial Lesions with High Signal Intensity on T1-weighted MR Images: Differential Diagnosis. RadioGraphics. 2012; 32 (2): 499-516.
[16] Goadsby PJ, Lollin Y, Kocen RS. Pseudopseudohypoparathyroidism and spinal cord compression. J Neurol Neurosurg Psychiatry. 1991; 54 (10): 929-931.
[17] Gomes MF, Camargo AMA, Sampaio TA, Graziozi MAO, Armond MC. Oral manifestations of Albright hereditary osteodystrophy: a case report. Rev Hosp Clínicas. 2002; 57: 161-166.
[18] Goswami M, Verma M, Singh A, Grewal H, Kumar G. Albright hereditary osteodystrophy: A rare case report. J Indian Soc Pedod Prev Dent. 2009; 27 (3): 184.
[19] HN, MA, TN, TH, ZZ. The fundamental architecture of the microvasculature of the basal ganglia and changes in senility. Neuropathology. 1998; 18 (1): 47-54.
[20] Hansen DW, Nebesio TD, DiMeglio LA, Eugster EA, Imel EA. Prevalence of Nephrocalcinosis in Pseudohypoparathyroidism: Is Screening Necessary? J Pediatr. 2018; 199: 263-266.
[21] Heaney RP, Barger-Lux MJ, Dowell MS, Chen TC, Holick MF. Calcium Absorptive Effects of Vitamin D and Its Major Metabolites1. J Clin Endocrinol Metab. 1997; 82 (12): 4111-4116.
[22] Hosojima H, Morimoto S, Uchida K, Yamamoto I, Kigoshi T, Azukizawa S, et al. Pseudohypoparathyroidism (PHP) type II and selective hypoaldosteronism in a patient with retinitis pigmentosa. Jpn J Med. 1984; 23 (2): 144-148.
[23] Iwase T, Yoshida M, Hashizume Y, Yazawa I, Takahashi S, Ando T, et al. Intracranial vascular calcification with extensive white matter changes in an autopsy case of pseudopseudohypoparathyroidism. Neuropathology. 2019; 39 (1): 39-46.
[24] Jun JE, Park SY, Jeong IK, Hwang YC, Ahn KJ, Chung HY. Delayed diagnosis of pseudohypoparathyroidism type 1a with rare hypothyroidism since childhood. Oxf Med Case Rep. 2022; 2022 (8): omac080.
[25] Kapoor S, Gogia S, Paul R, Banerjee S. Albright's hereditary osteodystrophy. Indian J Pediatr. 2006; 73: 153-156.
[26] Kim YS, Park J, Park Y, Hwang K, Koo DL, Kim D, et al. Intracranial Cortical Calcifications in a Focal Epilepsy Patient with Pseudohypoparathyroidism. J Epilepsy Res. 2016; 6 (1): 31-35.
[27] Kobayashi S, Yamadori I, Miki H, Ohmori M. Idiopathic nonarteriosclerotic cerebral calcification (Fahr's disease): an electron microscopic study. Acta Neuropathol (Berl). 1987; 73 (1): 62-66.
[28] Li P, Huang L, Zhao Z, Ye X, Liu Z. Spinal-cord compression related to pseudohypoparathyroidism. J Clin Neurosci Off J Neurosurg Soc Australas. 2011; 18 (1): 143-145.
[29] Macfarlane RJ, Han Ng B, Gamie Z, Masry MAE, Velonis S, Schizas C, et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother. 2008; 9 (5): 767-786.
[30] Manabe Y, Araki M, Takeda K, Yokota S, Kimura T. Pseudohypoparathyroidism with striopallidodentate calcification–a case report and review of the literature. Jpn J Med. 1989; 28 (3): 391-395.
[31] Mantovani G. Pseudohypoparathyroidism: Diagnosis and Treatment. J Clin Endocrinol Metab. 2011; 96 (10): 3020-3030.
[32] Mantovani G, Bastepe M, Monk D, de Sanctis L, Thiele S, Usardi A, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat Rev Endocrinol. 2018; 14 (8): 476-500.
[33] Mantovani G, Ferrante E, Giavoli C, Linglart A, Cappa M, Cisternino M, et al. Recombinant Human GH Replacement Therapy in Children with Pseudohypoparathyroidism Type Ia: First Study on the Effect on Growth. J Clin Endocrinol Metab. 2010; 95 (11): 5011-5017.
[34] Marguet C, Mallet E, Basuyau JP, Martin D, Leroy M, Brunelle P. Clinical and biological heterogeneity in pseudohypoparathyroidism syndrome. Results of a multicenter study. Horm Res. 1997; 48 (3): 120-130.
[35] Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP. Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr. 1997; 131 (2): 252-257.
[36] Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D Levels and Bone Turnover in Epilepsy Patients Taking Carbamazepine or Oxcarbazepine. Epilepsy. 2006; 47 (3): 510-515.
[37] Moody DM, Bell MA, Challa VR. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. Am J Neuroradiol. 1990; 11 (3): 431-439.
[38] Mouallem M, Shaharabany M, Weintrob N, Shalitin S, Nagelberg N, Shapira H, et al. Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha. Clin Endocrinol Oxf. 2008; 68 (2): 233-239.
[39] Najim MS, Ali R, Awad M, Omer A. Pseudohypoparathyroidism presenting with seizures: a case report and literature review. Intractable Rare Dis Res. 2020; 9 (3): 166-170.
[40] Nettekoven S, Ströhle A, Trunz B, Wolters M, Hoffmann S, Horn R, et al. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr. 2008; 167 (12): 1369-1377.
[41] Okada K, Iida K, Sakusabe N, Saitoh H, Abe E, Sato K. Pseudohypoparathyroidism-associated spinal stenosis. Spine. 1994; 19 (10): 1186-1189.
[42] PRENTICE R. J. Pseudohypoparathyroidism: a case report. J Clin Endocrinol Metab. 1954; 14 (9): 1069-1073.
[43] Ritter C, Göbel CH, Liebig T, Kaminksy E, Fink GR, Lehmann HC. An epigenetic cause of seizures and brain calcification: pseudohypoparathyroidism. The Lancet. 2015; 385 (9979): 1802.
[44] SP, Narayanaswamy null, Mathias NJ, Konan VK. Pseudohypoparathyroidism-A Rare Cause of Seizures in a Young Male. J Assoc Physicians India. 2023; 71 (1): 1.
[45] Salemi P, Skalamera JM, Olson, Dickson LE, Germain-Lee EL. Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI. J Clin Endocrinol Metab. 2017; 103 (1): 158-168.
[46] Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsy. 2017; 58 (4): 512-521.
[47] Srivastava G, Apovian C. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. Curr Obes Rep. 2018; 7 (2): 147-161.
[48] Sunder R, Singh M. Pseudohypoparathyroidism: a series of three cases and an unusual presentation of ocular tetany. Anaesthesia. 2006; 61 (4): 394-398.
[49] Swami A, Kar G. Intracranial hemorrhage revealing pseudohypoparathyroidism as a cause of fahr syndrome. Case Rep Neurol Med. 2011; 2011: 407567.
[50] Wang Y, Xu C, Xu Z, Ji C, Liang J, Wang Y, et al. Depolarized GABAergic Signaling in Subicular Microcircuits Mediates Generalized Seizure in Temporal Lobe Epilepsy. Neuron. 2017; 95 (1): 92-105. e5.
[51] Weinstein L. S. The Stimulatory G Protein α -Subunit Gene: Mutations and Imprinting Lead to Complex Phenotypes. J Clin Endocrinol Metab. 2001; 86 (10): 4622-4626.
[52] Yamada K, Tamura Y, Yamamoto M, Kumagai A. Effect of calcium administration on renal responsiveness to parathyroid hormone in pseudohypoparathyroidism type I and II -- in comparison with normal, idiopathic and surgical hypoparathyroidism. Endocrinol Jpn. 1979; 26 (2): 147-157.
[53] Yamamoto Y, Noto Y, Saito M, Ichizen H, Kida H. Spinal cord compression by heterotopic ossification associated with pseudohypoparathyroidism. J Int Med Res. 1997; 25 (6): 364-368.
[54] Yin XM, Lin JH, Cao L, Zhang TM, Zeng S, Zhang KL, et al. Familial paroxysmal kinesigenic dyskinesia is associated with mutations in the KCNA1 gene. Hum Mol Genet. 2018; 27 (4): 625-637.
[55] Pseudohypoparathyroidism: Diagnosis and Treatment | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic [online].
[56] GNAS GNAS complex locus [Homo sapiens (human)] - Gene - NCBI [online]. [cited August 17, 2023]. Available at: https://www.ncbi.nlm.nih.gov/gene/2778#gene-expression.
[57] Pseudohypoparathyroidism Type Ia: Late Presentation with Intact Mental Development - Rutter - 1998 - Journal of Bone and Mineral Research - Wiley Online Library [online].
[58] Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification | Neurology [online].
[59] Cognitive and behavioral phenotype of children with pseudohypoparathyroidism type 1A - Perez - 2018 - American Journal of Medical Genetics Part A - Wiley Online Library.
[60] EBSCOhost | 70956799 | The nature of the calcified structures in the brain in hypoparathyroidism.
Cite This Article
  • APA Style

    Mpung Mansoj, H., Dieynabou Sow, A., Ndiaye, M. (2023). Senegalese Experience of Pseudo Hypoparathyroidism About Three Cases at the Department of Neurology in Fann Teaching Hospital. International Journal of Medical Case Reports, 2(4), 28-35. https://doi.org/10.11648/j.ijmcr.20230204.12

    Copy | Download

    ACS Style

    Mpung Mansoj, H.; Dieynabou Sow, A.; Ndiaye, M. Senegalese Experience of Pseudo Hypoparathyroidism About Three Cases at the Department of Neurology in Fann Teaching Hospital. Int. J. Med. Case Rep. 2023, 2(4), 28-35. doi: 10.11648/j.ijmcr.20230204.12

    Copy | Download

    AMA Style

    Mpung Mansoj H, Dieynabou Sow A, Ndiaye M. Senegalese Experience of Pseudo Hypoparathyroidism About Three Cases at the Department of Neurology in Fann Teaching Hospital. Int J Med Case Rep. 2023;2(4):28-35. doi: 10.11648/j.ijmcr.20230204.12

    Copy | Download

  • @article{10.11648/j.ijmcr.20230204.12,
      author = {Halladain Mpung Mansoj and Adjaratou Dieynabou Sow and Moustapha Ndiaye},
      title = {Senegalese Experience of Pseudo Hypoparathyroidism About Three Cases at the Department of Neurology in Fann Teaching Hospital},
      journal = {International Journal of Medical Case Reports},
      volume = {2},
      number = {4},
      pages = {28-35},
      doi = {10.11648/j.ijmcr.20230204.12},
      url = {https://doi.org/10.11648/j.ijmcr.20230204.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijmcr.20230204.12},
      abstract = {Pseudohypoparathyroidism is a group of rare, related and highly heterogeneous disorders characterized by target organ resistance to the action of parathyroid hormone. Pseudohypoparathyroidism and related disorders are caused by genetic and/or epigenetic changes resulting in downregulation of a cyclic adenosine mono phosphate generator primarily linked to the GNAS gene, patients who have experienced hormonal parathyroid (hypocalcemia and hyperphosphatemia resistant to parathyroid hormone with characteristic skeletal and developmental changes. Multiple transcript variants encoding different isoforms have been found for this gene. Mutations in this gene result in pseudohypoparathyroidism type 1a, pseudohypoparathyroidism type 1b, hereditary osteodystrophy; Albright, pseudohypoparathyroidism, McCune-Albright syndrome, progressive bone heteroplasia, polyostotic fibrous dysplasia of bone, and certain pituitary tumors Here we report a series of 3 cases carrying pseudohypopathyroidism, their sociodemographic, clinical and paraclinical aspects as well as therapeutic.
    },
     year = {2023}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Senegalese Experience of Pseudo Hypoparathyroidism About Three Cases at the Department of Neurology in Fann Teaching Hospital
    AU  - Halladain Mpung Mansoj
    AU  - Adjaratou Dieynabou Sow
    AU  - Moustapha Ndiaye
    Y1  - 2023/12/18
    PY  - 2023
    N1  - https://doi.org/10.11648/j.ijmcr.20230204.12
    DO  - 10.11648/j.ijmcr.20230204.12
    T2  - International Journal of Medical Case Reports
    JF  - International Journal of Medical Case Reports
    JO  - International Journal of Medical Case Reports
    SP  - 28
    EP  - 35
    PB  - Science Publishing Group
    SN  - 2994-7049
    UR  - https://doi.org/10.11648/j.ijmcr.20230204.12
    AB  - Pseudohypoparathyroidism is a group of rare, related and highly heterogeneous disorders characterized by target organ resistance to the action of parathyroid hormone. Pseudohypoparathyroidism and related disorders are caused by genetic and/or epigenetic changes resulting in downregulation of a cyclic adenosine mono phosphate generator primarily linked to the GNAS gene, patients who have experienced hormonal parathyroid (hypocalcemia and hyperphosphatemia resistant to parathyroid hormone with characteristic skeletal and developmental changes. Multiple transcript variants encoding different isoforms have been found for this gene. Mutations in this gene result in pseudohypoparathyroidism type 1a, pseudohypoparathyroidism type 1b, hereditary osteodystrophy; Albright, pseudohypoparathyroidism, McCune-Albright syndrome, progressive bone heteroplasia, polyostotic fibrous dysplasia of bone, and certain pituitary tumors Here we report a series of 3 cases carrying pseudohypopathyroidism, their sociodemographic, clinical and paraclinical aspects as well as therapeutic.
    
    VL  - 2
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Department of Neurology, Cheikh Anta Diop University, Fann Teaching Hospital, Dakar, Senegal

  • Department of Neurology, Cheikh Anta Diop University, Fann Teaching Hospital, Dakar, Senegal

  • Department of Neurology, Cheikh Anta Diop University, Fann Teaching Hospital, Dakar, Senegal

  • Sections